We aim to revolutionize RAS-addicted cancer care through discovery, development, and delivery of innovative targeted medicines. #WeAreRevolutionaries
Joined August 2025
- Tweets 18
- Following 0
- Followers 1,104
- Likes 0
17 Photos and videos
#ASCO26 reinforced what we know: RAS-targeted therapies are reshaping cancer treatment. Our Phase 3 RASolute 302 results demonstrate meaningful progress for patients. Excited about what's ahead.
2
9
31
1,285
RASolute 302 Phase 3 results were presented at #ASCO26: All primary and key secondary endpoints met for previously treated metastatic pancreatic cancer. Results published in @NEJM. ir.revmed.com/news-releases/…
4
13
35
5,997
Phase 1/2 data for our RAS(ON) multi-selective inhibitor published in @NEJM.
Findings contributed to the scientific and clinical rationale for Phase 3 RASolute 302 trial in metastatic RAS mutant pancreatic cancer.
More: ir.revmed.com/news-releases/…
1
8
25
1,986
Today we reported our first quarter 2026 financial results and shared updates on our continued progress advancing targeted therapies for patients with RAS-addicted cancers.
Read the full press release: ir.revmed.com/news-releases/…
2
4
19
1,565
The FDA has issued a “safe to proceed” letter allowing Revolution Medicines to initiate an expanded access treatment protocol for our investigational RAS(ON) multi-selective inhibitor in patients with previously treated metastatic PDAC.
Our statement: ir.revmed.com/news-releases/…
6
19
67
4,595
We presented preclinical data highlighting an innovative new class of mutant-targeted catalytic RAS(ON) inhibitors at the @AACR Annual Meeting.
Read more: ir.revmed.com/news-releases/…
#AACR26
1
2
23
2,423
Today at @AACR, we announced updated clinical data from two Phase 1/2 trials evaluating our RAS(ON) multi-selective inhibitor in patients with previously untreated metastatic pancreatic cancer.
Read more: ir.revmed.com/news-releases/…
#AACR26 #PancreaticCancer
2
3
18
1,489
We will present detailed results from the Phase 3 RASolute 302 clinical trial during a Plenary Session at the @ASCO Annual Meeting.
Learn more: ir.revmed.com/news-releases/…
#ASCO26
1
3
25
1,068
Today we announced updated Phase 1 data for our RAS(ON) G12D-selective inhibitor in patients with previously treated KRAS G12D non-small cell lung cancer at the @AACR Annual Meeting.
More: ir.revmed.com/news-releases/…
#AACR26 #LungCancer
1
7
45
2,399
Thank you @drughunter_com for recognizing our investigational RAS(ON) inhibitor as 2025 Molecule of the Year. We're honored and remain committed to advancing innovation and new treatment approaches for patients with RAS-driven cancers. drughunter.com/articles/dara…
1
1
11
1,219
Unprecedented overall survival benefit from Phase 3 RASolute 302 in previously treated metastatic pancreatic cancer.
Read the press release: ir.revmed.com/news-releases/…
#Oncology #PancreaticCancer
4
12
64
21,654
Study participants have started treatment in RASolute 303, a global Phase 3 trial evaluating our investigational therapy as first line treatment for patients with metastatic pancreatic cancer.
Learn more: ir.revmed.com/news-releases/…
1
6
798
Revolution Medicines retweeted
Mar 12
A new @PennCancer study shows how a cancer interception strategy can target pancreatic cancer before it forms: spr.ly/6012B6Kg3Q
@ScienceMagazine @BenStanger01 @BasserBRCA
6
8
1,436
We will have 9 oral & poster presentations at @AACR in San Diego (April 17-22). Presentations reflect breadth of our RAS(ON) pipeline, with data spanning multiple tumor types, including ongoing efforts to address resistance in RAS driven cancers.
More: ir.revmed.com/news-releases/…
6
511
Revolution Medicines presents at the @AACR Special Conference on RAS (March 7, Los Angeles), including a keynote from Mallika Singh, SVP Translational Research:
"Targeting the oncogenic state of RAS: Lessons from tri-complex inhibitors"
#AACRras26
2
3
779
We're proud to announce @My_Green_Lab has recertified all Revolution Medicines labs, with 100% achieving Green Level, the highest certification level.
This accomplishment reflects our commitment to sustainable laboratory practices across the organization.
#SustainableScience
1
1
291
We're joining X on #WorldCancerDay 🧬
Millions of patients and families facing cancer deserve better options. For those with RASmutant cancers, advancing innovative therapies offers hope. Today, we honor patients, caregivers, and researchers who are leading the way.
1
235